1-3 of 3
Clemens Leitgeb
Close
Sort by
Journal Articles

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Clinical Trials & Observations
Heinz Ludwig, Hedwig Kasparu, Clemens Leitgeb, Elisabeth Rauch, Werner Linkesch, Niklas Zojer, Richard Greil, Adelheid Seebacher, Ludek Pour, Adalbert Weißmann, Zdeněk Adam
Journal: Blood
Blood (2014) 123 (7): 985–991.
https://doi.org/10.1182/blood-2013-08-521468
Published: 2014
Journal Articles

Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated

Heinz Ludwig, Hedwig Kasparu, Richard Greil, MD, Clemens Leitgeb, Ercan Müldür, Elisabeth Rauch, Niklas Zojer, Eva Maria Autzinger, Werner Linkesch, Thomas Kuhr, Ludek Pour, MD, PhD, Zdenek Adam
Journal: Blood
Blood (2012) 120 (21): 943.
https://doi.org/10.1182/blood.V120.21.943.943
Published: 2012
Journal Articles

Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians

Heinz Ludwig, MD, Hedwig Kasparu, Werner Linkesch, MD, Josef Thaler, Richard Greil, MD, Clemens Leitgeb, Daniel Heintel, Elisabeth Rauch, Niklas Zojer, Ludek Pour, Adelheid Seebacher, Zdenek Adam
Journal: Blood
Blood (2011) 118 (21): 2928.
https://doi.org/10.1182/blood.V118.21.2928.2928
Published: 2011